Genomic profiling of lung adenocarcinoma cohorts has identified ALK gene rearrangements in approximately 3–7% of NSCLC cases, predominantly in younger, non-smoking patients [16,17]. This evidence concerns the gene ALK and non-small cell lung carcinoma.